2009 Fiscal Year Final Research Report
Basic research of peptide vaccine as therapeutic cancer vaccine
| Project/Area Number |
17016074
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research on Priority Areas
|
| Allocation Type | Single-year Grants |
|---|
| Review Section |
Biological Sciences
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
ITOH Kyogo Kurume University, 医学部, 教授 (50125499)
|
|---|
| Project Period (FY) |
2005 – 2009
|
| Keywords | 抗原ペプチド / がん治療ペプチドワクチン / キラーT細胞 / ペプチド抗体 / バイオマーカー |
|---|
| Research Abstract |
We identified relatively large numbers of peptide antigens from human tumor associated antigens that were recognized by HLA-class IA-restricted cytotixic T lymphocytes. These peptide antigens could bind to different types of HLA-class IA molecules, including HLA-A2 (0201, 0206, and 0207), A3, A1101, A2402, A26, A3101, and A3303. At least one of these HLA molecules were expressed in the vast majority of Japanease (>98%) and Asians (>90%), and the other ethnics (>70%). Therefore, these identified peptides could be applicable for peptide-based cancer immunotherapy to cancer in the world. We also found that IgG specific to these peptides were detectable in plasma of cancer patients, suggesting the reactivity of these peptides to T helper cells. These results allowed us a pre-vaccination measurement of peptide-specific IgG highly reactive to peptides, and administration of only reactive peptides to cancer patients (personalized peptide vaccination). Indeed, we recently reported these personalized peptide vaccination provided favorite clinical responses to cancer patients through a randomized clinical trial. Collectively, we could provide scientific basis of peptide vaccine as therapeutic cancer vaccine.
|
-
[Journal Article] A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer2010
Author(s)
Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K
-
Journal Title
Cancer Immunol. Immunotherapy (in press)
-
-
-
-
-
-
-
-
-
[Journal Article] Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.2005
Author(s)
Yajima N, Yamanaka R, Mine T, Tsuchiya N, Honma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A, Shigemori M, Itoh K, Tanaka R.
-
Journal Title
Clin Cancer Res. 11
Pages: 5900-11
-
-
-
-
-
-
[Presentation] HLA-24A陽性進行癌を対象としたテーラーメイド型ペプチドワクチン療法の第I相試験および継続投与試験2008
Author(s)
寺崎瑞彦, 野口正典, 伊東恭悟, 内藤誠二, 植村天受, 赤座英之, 渋井壮一郎, 藤巻高光, 青木友和, 峯田寿裕, 梶原浩司
Organizer
第46回日本癌治療学会総会
Place of Presentation
名古屋
Year and Date
20081030-20081101
-
[Presentation] Survival benefit of personalized peptide vaccine for advanced cancer patients: Up date of enrolled 475 cases2008
Author(s)
峯孝志, 野口正典, 藤堂省, 柳本泰明, 植村天受, 山中龍也, 嘉村敏治, 岡正朗, 奥野清隆, 松本和将, 山田亮, 伊東恭悟
Organizer
第67回日本癌学会学術総会
Place of Presentation
名古屋
Year and Date
20081028-20081030
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
